ABSTRACT
INTRODUCTION
Hypertension (HTN) is a key factor in the development of cardiovascular disease. The increase in blood pressure (BP) from optimal levels correlates with coronary heart disease, stroke, heart failure, sudden death, chronic kidney disease, and peripheral arterial disease, which are the leading causes of disease and death in the world. HTN affects 30-40% of the adult population. In addition, BP increases with age so that the prevalence of HTN in the elderly is over 50% [1] [2] [3] . In Spain, 33% of adults are hypertensive and the prevalence of HTN in the population over 60 years of age is close to 70%
[4]. Antihypertensive treatment is considered to be one of the main achievements in medicine in recent decades, since reducing high BP significantly reduces HTN-related morbidity and mortality [5] .
Most of the basic concepts regarding HTN are based on the classical measurement of BP in the Electronic supplementary material The online version of this article (doi:10.1007/s40119-015-0042-2) contains supplementary material, which is available to authorized users.
doctor's office. However, the main limitation of this method is that it only offers a momentary BP value that, in addition, is subject to factors that may occasionally change it [6] [7] [8] . To optimize assessing true BP values, techniques have been developed to self-measure BP at home, also called home BP monitoring (HBPM) and automated BP measurement over 24 h or ambulatory BP monitoring (ABPM). The BP levels obtained using HBPM [9] [10] [11] [12] [13] [14] and those recorded using ABPM [11, [15] [16] [17] [18] [19] [20] [21] The objective of this article was to review the studies on the effect of olmesartan-based antihypertensive therapies on the main prognostic indicators related to ambulatory BP.
METHODS
Olmesartan was chosen to perform this review because recent studies analyzing the abovementioned variables have been developed using this drug. A PubMed search was conducted combining the terms 'olmesartan', 'olmesartan and hydrochlorothiazide', 'olmesartan and amlodipine', 'olmesartan and hydrochlorothiazide and amlodipine', 'home blood pressure measurement', and 'ambulatory blood pressure monitoring'. Furthermore, additional searches were conducted using the terms pertaining to treatments, and 'blood pressure control', 'ambulatory blood pressure control', 'morning surge', 'blood pressure variability', and 'chronotherapy', selecting the studies according to the review objective.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author. Table 2 . In low-to-moderate-risk patients without diabetes or kidney disease, a relatively low use of combined treatments was observed, being control rates less than 50%. This figure was probably an expression of therapeutic inertia or nihilism. In higher-risk patients, with diabetes or kidney disease, the therapeutic effort was higher but the control rates were even more unfavorable.
CURRENT INDICATIONS FOR AMBULATORY BP MEASUREMENT
Using combined antihypertensive treatment earlier and a more systematic indication for triple therapy when control is not achieved with two drugs might result in improvements in control rates. The most appropriate triple combination has been considered to be one that includes a renin-angiotensin system blocker, a calcium-channel blocker, and a diuretic In another sub-analysis, in this case the BP-CRUSH study (Blood pressure control in all subgroups with hypertension; ClinicalTrials.gov number, NCT00791258), with a similar design to the previous one and including 243 patients, the degree of ambulatory BP control obtained with the full doses of olmesartan, amlodipine, based on initial measurements. The HONEST study will provide data on the prognostic value of home measurements taken during follow-up [35] . In the first publication of results, regarding the short-term efficacy of the olmesartan-based treatment guidelines, it was reported that the percentage of patients who achieved adequate control of clinic systolic BP (systolic BP \140 mmHg) and home systolic BP (systolic BP \135 mmHg), simultaneously, increased from 7.9% to 38.9% after 16 weeks of followup [36] .
CIRCADIAN RHYTHM AND CHRONOTHERAPY
The relationship between absolute ambulatory BP levels and cardiovascular morbidity and mortality is well established. Of the different periods typically analyzed (24 h, day and night), nighttime BP is the variable that is best correlated with the prognosis. In addition, the relationship between daytime BP and nighttime BP (circadian profile) also predicts HTN-related asymptomatic target organ damage and cardiovascular events [ patients were randomized to take olmesartan in the morning or at night and the reductions in clinic BP, morning home BP, urinary excretion of albumin, and electrocardiographic parameters of left ventricular hypertrophy were similar in patients who received the treatment in the morning or at night [43] .
MORNING SURGE IN BP
The increase in BP that is observed when waking and especially when starting daily activity is considered a physiological process. However, there is a controversy about whether or not an excessive morning BP surge may cause a negative prognosis [8] . In this sense, it has been recognized that the antihypertensive treatment that minimizes the morning BP surge, without causing excessive reductions over the rest of the day, has an added beneficial effect.
One of the most studied related variables is the trough-to-peak ratio, considering the peak time as the 2 consecutive hours with the largest reduction in BP in the period between 2 and 8 h after taking the treatment and the trough time 23 and 24 h after taking the treatment, considering ideal the best proximity to the unit that reflects a homogeneous effect over 24 h. Two recent studies with olmesartan-based treatment have measured this variable. Both in the EXPO study [45, 46] and in Bilo et al. [47] , the treatment caused a lasting effect over the 24-h period, with a trough-to-peak ratio greater than 0.6. In the Bilo et al. [47] study, which also assesses this parameter with the olmesartan and amlodipine combinations, a more favorable trough-to-peak ratio was observed in patients who received the combination. Use of longacting antihypertensive drugs should be of key importance for adequate BP morning surge control. As shown in a recent meta-analysis, losartan was less effective than other angiotensin receptor blockers for controlling 24-h BP [48] .
BP VARIABILITY
Although the cardiovascular complications of HTN are essentially related to the absolute BP levels, increased BP variability may have an added deleterious effect. Thus, relationships between cardiovascular morbidity/mortality and very-short-term variability (beat to beat), short term (in a 24-h period), long term (between days), and very long term (between doctor's visits) have been described [49, 50] .
There is a close relationship between elevated BP levels, a higher cardiovascular risk, and an increased variability in BP assessed using ABPM [23] . In most of the studies mentioned so far that have assessed this indicator, a reduction in BP variability related to the reduction in absolute BP levels caused by the various treatments was observed. Thus, certain results are of additional interest. In a post hoc analysis of Japan combined treatment with olmesartan and a calcium-channel blocker versus olmesartan and diuretics randomized efficacy study, in which the patients initially treated with olmesartan were randomized to receive additional treatment with azelnidipine or with hydrochlorothiazide, the patients treated with olmesartan and the calcium-channel blocker presented a higher reduction in day-to-day variability as assessed using HBPM compared to that observed in patients who received olmesartan and the diuretic, despite similar reductions in the absolute home BP levels. In addition, a possible relationship was observed between the reduction in variability and an improvement in a marker of asymptomatic target organ damage, such as aortic rigidity, assessed by measuring carotid-femoral pulse wave velocity [51] .
One of the physiopathological changes most closely related to increased BP variability is sympathetic hyperactivity. Accordingly, the results of a sub-analysis of the previously mentioned studies are also of interest. Based on the HONEST data, a higher relative reduction in heart rate was observed in HBPM readings in patients with higher baseline ambulatory systolic BP and heart rate. This tendency was clear in the patient subgroup with chronic kidney disease, in which sympathetic hyperactivity is usually greater.
The authors of this study concluded that treatment with olmesartan may have an added beneficial effect on intrarenal circulation in patients with chronic kidney disease and the resulting sympathetic hyperactivity [52] .
LIMITATIONS
Most of the studies on the effect of olmesartan and olmesartan-based treatments on variables 
